WCN26-1872 PRESERVATION OF HUMORAL IMMUNITY AND RESPONSE TO VACCINATION AND INFECTION IN FELZARTAMAB-TREATED PATIENTS WITH IgA NEPHROPATHY: DATA FROM THE PHASE 2 IGNAZ STUDY

Read full text Summarise with VIRAT
Authors: Millie Shah, Lisa Kivman, Tabea Kräft, Brian M. Schwartz, Nicholas S. Jones, Valeria V. Beckett, Jingxian Chen, Peishan Liu-Snyder, Uptal D. Patel, Donna Flesher, Jonathan Barratt
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Depletion of B lineage cells, including plasma cells, is a promising therapeutic strategy for immune-mediated diseases but can potentially reduce humoral immunity. Felzartamab, a fully human anti-CD38 monoclonal antibody targeting CD38+ plasmablasts and plasma cells, is under investigation in multiple immune-mediated diseases including immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN). Results in PMN demonstrated preservation of vaccine immunity among felzartamab-treated patients.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Monoclonal and Polyclonal Antibodies Research Multiple Myeloma Research and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104419–104419
Publication date
25 March 2026
Language
EN